The interplay and sequencing of amyloid, tau, metabolism, atrophy and clinical symptoms in participants with dysexecutive Alzheimer’s disease are uncertain but are areas of ongoing investigation. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.